ライフサイエンスコーパス: immunogen

1 ZIKV vaccines using the envelope proteins as immunogens).

2 sylated, soluble full-length protein vaccine immunogen.

3 oader specificity and higher affinity to the immunogen.

4 e presentation of a native-like trimeric Env immunogen.

5 eleted antigen could be a better HCV vaccine immunogen.

6 suggesting that CTD1 could be a good vaccine immunogen.

7 vector and 7 were derived from the HIVconsv immunogen.

8 ay represent a next-generation candidate HIV immunogen.

9 tralizing antibody profile determined by the immunogen.

10 stabilization for use as a candidate vaccine immunogen.

11 eveloped as a research reagent and candidate immunogen.

12 e utilize a mammalian non-self-antigen as an immunogen.

13 helical peptide epitope to create a superior immunogen.

14 of antibody ID to viruses and other complex immunogens.

15 uctural blueprints to design next-generation immunogens.

16 study of HIV spikes and their development as immunogens.

17 ing a potential route to engineer E2 vaccine immunogens.

18 bs alone and complexed with 426c-based gp120 immunogens.

19 hat can be elicited with currently available immunogens.

20 ture-based design of betacoronavirus vaccine immunogens.

21 both autologous and heterologous to vaccine immunogens.

22 izing the nature of the priming and boosting immunogens.

23 r surface that probably function as dominant immunogens.

24 le carriers, for example, proteins, to yield immunogens.

25 se induced by the structurally unconstrained immunogens.

26 ntigen-binding conformations for recognizing immunogens.

27 ults should help guide the design of vaccine immunogens.

28 sion will aid in defining targets of vaccine immunogens.

29 nd UL47 (tegument protein VP13/14) as T cell immunogens.

30 multivalent mixtures of HIV-1 envelope (Env) immunogens.

31 uccessfully selected as potential Cry1A(b)16 immunogens.

32 n of T-independent antigens into T-dependent immunogens.

33 importance of both serotypes of gD and gB as immunogens.

34 ng human Ab responses to viruses and protein immunogens.

35 more efficiently with suitably optimized GP immunogens.

36 s thus a critical goal for the design of Env immunogens.

37 re immunization with a succession of related immunogens.

38 like particles (VLP) expressing HA and NA as immunogens.

39 ave been proposed as preferred HIV-1 vaccine immunogens.

40 at may be exploited in designing HIV vaccine immunogens.

41 may help inform the design of future vaccine immunogens.

42 ) and CD8(+) T-cell responses to all vaccine immunogens.

43 e to target and incorporate into HIV vaccine immunogens.

44 ar epitopes in NHP studies with HIV-1 or SIV immunogens.

45 hemagglutinin (HA) and neuraminidase (NA) as immunogens.

46 e excellent templates for developing soluble immunogens.

47 ne response to competing antigens in complex immunogens.

48 acilitating the development of engineered V2 immunogens.

49 on, structural studies, and use as potential immunogens.

50 and led directly to the development of novel immunogens.

51 d to design novel hemagglutinin (HA) vaccine immunogens.

52 us-neutralizing antibodies when delivered as immunogens.

53 properties offer a template for H7N9 vaccine immunogens, a promising candidate therapeutic, and a too

54 gagement will help researchers to develop an immunogen able to elicit antibodies that block HIV-1 tra

55 These observations encourage the search for immunogens able to elicit this kind of response in preve

56 Furthermore, this immunogen activates naive B cells expressing the human g

57 Germline-targeting immunogens aim to initiate bnAb induction by activating

58 ing the development and testing of promising immunogens aimed at the elicitation of bnAbs.

59 vaccinia virus Ankara (MVA) (M), and protein immunogens, all expressing virus-like particles (VLPs) d

60 Breadth was elicited with a single trimer immunogen and did not require additional envelope divers

61 irus (VACV)--a gold standard vaccine--as the immunogen and ectromelia virus (ECTV) as the pathogen to

62 there was sequence homology between vaccine immunogen and endogenous virus.

63 context of genetic mismatch between vaccine immunogen and endogenous virus; however, these commonly

64 re there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the majo

65 cine is primarily determined by the envelope immunogen and is not substantially broadened by includin

66 ngs demonstrated gCTB's potential as an oral immunogen and point to a potential role of N-glycosylati

67 glycoprotein (Env) have long been sought as immunogens and as reagents for analysis of Env structure

68 ze the genetic dissimilarity between vaccine immunogens and contemporary circulating viruses, computa

69 enting a step towards the rational design of immunogens and drugs inhibiting HCV entry.

70 immunized these bovines with different VEEV immunogens and evaluated the protective efficacy of puri

71 The study of gp120 Env immunogens and immune correlates of risk has resulted in

72 Here, we tested multiple immunogens and immunization strategies head-to-head to d

73 cursor naive B cells bind germline-targeting immunogens and occur at sufficient frequency in humans f

74 imitations of the current germline-targeting immunogens and of the animal models used to test them, a

75 igenic and immunogenic potential of E2-based immunogens and provide a pathway for the development of

76 senting a potential target for the design of immunogens and therapeutics.

77 e use of recombinant peptide:MHC monomers as immunogens, and subsequently relies on multimers to pre-

78 evelopers a "glycosylation target" for their immunogens, and they show how protein production variabl

79 or B cells targeted by an engineered priming immunogen are relatively common among humans.

80 all immune cells responding to a foster dam immunogen are the product of the foster pup's thymus.

81 New HIV-1 envelope immunogens are being engineered to selectively expose th

82 work in the field suggests that improved Env immunogens are forthcoming, and it is therefore importan

83 Our immunogens are therefore prototypes of vaccine candidate

84 erefore, these structurally constrained V1V2 immunogens are vaccine prototypes targeting the V1V2 dom

85 s, and their eOD-GT8 affinities support this immunogen as a candidate human vaccine prime.

86 nal diversity to the pool of native-like Env immunogens as key components of strategies to induce bnA

87 hasis should be placed on optimizing the Env immunogen, as the neutralization profile achieved by the

88 This resulted in epitope-based immunogens based on a cyclic defensin protein, as well a

89 Here we show that immunogens based on full-length S DNA and S1 subunit pro

90 Two recent publications report the design of immunogens based on the conserved stalk domain of the in

91 tant implications for development of vaccine immunogens based on the newly identified m336 epitope as

92 tudy, we rationally designed several vaccine immunogens based on the structure of a conserved epitope

93 heir development, suggesting that sequential immunogen-based vaccine regimens will likely need to inc

94 cient Env derivatives can be used as priming immunogens because they should engage and activate a mor

95 We found that both types of immunogen boosts enhanced potentially protective antibod

96 tly, and half of GC B cells did not bind the immunogen but nonetheless exhibited biased VH use, V(D)J

97 tructural modification of the HIV-1 envelope immunogen by cross-linking of gp140 with the CD4-mimetic

98 e antigens can be converted into more potent immunogens by chemically coupling to a "carrier protein"

99 Here we show that an optimized Env immunogen can engage multiple glVRC01-class antibodies.

100 Thus, specifically designed Env immunogens can activate naive B cells expressing human B

101 We show here that such immunogens can be designed and that they induced conform

102 These studies suggest that glycopeptide immunogens can be designed to stabilize the most relevan

103 tial immunization with specifically designed immunogens can induce high levels of somatic mutation an

104 asize the strong priming effect improved DNA immunogens can induce, which are further expanded upon p

105 etition and indicate that germline-targeting immunogens can overcome these challenges with high-affin

106 These locked dimers are strong immunogen candidates for a next-generation vaccine.

107 l of HIV-1 vaccine research is the design of immunogens capable of inducing broadly neutralizing anti

108 Vaccine immunogens capable of re-eliciting these membrane proxim

109 measure the NII for different epitopes on an immunogen comprised of the receptor-binding domain from

110 nt regimens expressing the same SIV envelope immunogen consistently elicit antibodies that neutralize

111 altered angle of approach, we engineered an immunogen consisting of gp120 core in complex with the p

112 nish the first semisynthetic bacterial-based immunogen construct targeting S. dysgalactiae 2023.

113 est that appropriate modifications of trimer immunogens could further focus the immune response on ke

114 es against HIV in the next generation of HIV immunogens currently being developed.

115 l surface engineering on the next generation immunogen, DEKnull-2, provides an immunogenicity breakth

116 3 responses and demonstrated that continuous immunogen delivery could enhance nAb responses.

117 h virus escape and potentially contribute to immunogen design and antibody-based prophylactic therapy

118 quiring a systematic approach to Env mimetic immunogen design and evaluation of elicited responses.

119 recognition of Env, which may inform vaccine immunogen design and immunotherapeutic development.

120 Env and can be used to inform strategies for immunogen design and preparation.

121 These data inform immunogen design and suggest that it is useful to obscur

122 A concern in the trimer immunogen design field has been whether the latter off-t

123 , suggesting the importance of the region in immunogen design for maternal vaccines to prevent MTCT.I

124 Recent advances in immunogen design have provided soluble recombinant envel

125 tly isolated bNAbs, the rational approach to immunogen design is to make a stable version of the Env

126 itical for understanding how to improve upon immunogen design to inform further testing in human clin

127 nose-type glycans is an important feature in immunogen design, as glycans contribute to or influence

128 es for passive immunotherapy and for guiding immunogen design.

129 ass bNAbs and guidelines for structure-based immunogen design.

130 This new information might be useful in immunogen design.

131 cerning gp120 structure and the field of HIV immunogen design.

132 s structural characterization and guided Env immunogen design.

133 antibodies and represent a key component for immunogen design.

134 antibodies provides insights that may guide immunogen design.

135 evolution of this antibody family to inform immunogen design.

136 r understanding of its function and limiting immunogen design.

137 of these antibodies can provide insights for immunogen design.

138 aches based on germline-targeting and serial immunogen design.

139 for other env genes, thereby further guiding immunogen design.

140 Priming with an epitope-modified immunogen designed to activate germline antibody-express

141 Nonetheless, all trimeric and monomeric Env immunogens designed to date have failed to elicit such a

142 Here, we report the development of boosting immunogens designed to guide the genetic and functional

143 aluable new opportunities for ontogeny-based immunogens designed to select for rare V2-bNAb precursor

144 ility of sequentially administered, modified immunogens (designed to bind progressively more mature b

145 strates that in silico-designed global HIV-1 immunogens, designed for a human clinical trial, are cap

146 of these responses will help in defining new immunogen designs and neutralization targets for vaccine

147 he humoral responses elicited by these novel immunogen designs in nonhuman primates is critical for u

148 As promising cell-free immunogens, Dexo have been tested in previous clinical t

149 rast, repeated immunization with the priming immunogen did not.

150 by current HIV-1 envelope glycoprotein (Env) immunogens display narrow neutralizing activity with lim

151 y, sera from rabbits receiving V1V2-scaffold immunogens displayed Ab-dependent cellular phagocytosis

152 in boost regimen with these new gp120 trimer immunogens elicited potent neutralizing antibody respons

153 ctions of antibodies elicited by novel HIV-1 immunogens engineered to improve exposure of specific ep

154 We designed a panel of immunogens engrafting the V1V2 domain into trimeric and

155 Both boost immunogens enhanced the breadth of HIV-1 gp120 and V1V2

156 y of the VRC01-class bnAb germline-targeting immunogen eOD-GT8 60mer (60-subunit self-assembling nano

157 imization, we developed a germline-targeting immunogen (eOD-GT8) for diverse VRC01-class bnAbs.

158 e developed this principle into a two-phased immunogen evaluation pipeline to rank-order vaccine cand

159 responses than those to other envelope-based immunogens, even in animal models.

160 the present generation of native-like trimer immunogens, exemplified by the BG505 SOSIP.664 construct

161 In contrast, native-like immunogens failed to activate VRC01-class precursors.

162 Immunogens focused on an RBS-directed response will thus

163 These peptides may benefit the design of immunogens, focusing T cell responses on relevant marker

164 able from wild type, proving its value as an immunogen for a future generation of vaccines against th

165 strategy using the inter-species cytokine as immunogen for active immunization (TISCAI) to induce ant

166 purified with self-histones and was a potent immunogen for BALB/c mice.

167 often include multiple variants for a given immunogen for better coverage of the extensive viral div

168 effective HIV-1 envelope glycoprotein (Env) immunogen for elicitation of broadly neutralizing antibo

169 different C. difficile strains may be a good immunogen for stimulating B cell memory that encodes in

170 Env adds to the increasing pool of potential immunogens for a HIV-1 vaccine, particularly for clade C

171 line-reverted B cell receptors are candidate immunogens for eliciting VRC01-class bNAbs.

172 cept of using in silico-designed centralized immunogens for global HIV-1 vaccine development strategi

173 our study provides an arsenal of multivalent immunogens for HIV-1 vaccine development.

174 Thus, they are attractive immunogens for vaccine development.

175 and safe vector for the delivery of foreign immunogens for vaccine purposes.

176 on the HIV-1 env gene are current candidate immunogens for vaccine trials in humans.

177 ipid binding sites on 4E10 may aid design of immunogens for vaccines that include a lipid component i

178 tions for discriminating current pre-F-based immunogens from FI-RSV used in historical vaccine trials

179 This priming immunogen has demonstrated the ability to initiate a bnA

180 s far, the generation of centralized vaccine immunogens has been carried out at the level of individu

181 the pertactin protein, an acellular vaccine immunogen, has been reported in the United States.

182 cked guidance on how to assess whether their immunogens have optimal glycosylation.

183 These Env trimers when used as immunogens, have led to the first vaccine-induced neutra

184 may facilitate the design of V1V2-targeting immunogens.IMPORTANCE Many epitopes of the HIV envelope

185 We solved the X-ray structure of a cyclic immunogen in complex with the HCV1 antibody and confirme

186 y vaccination approaches including Tat as an immunogen in potential candidate vaccines or by developi

187 hile including multiple variants for a given immunogen in prime-boost vaccination strategies is one a

188 entative set of mAbs elicited by a model Env immunogen in rhesus macaques and comprehensively charact

189 tion of soluble, native-like envelope trimer immunogens in a conventional mouse model.

190 s of the SOSIP design are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1

191 d Der f from Dermatophagoides sp. are strong immunogens in humans.

192 mited experience with recombinant trimers as immunogens in nonhuman primates, which are typically use

193 haracterized the new trimers, tested them as immunogens in rabbits, and found that the blocking glyca

194 When we tested these trimers as immunogens in rabbits, the induction of V3 non-NAbs was

195 cination strategy, which uses mismatched Gag immunogens in the TamoVac 01 phase IIa trial.

196 mple modification for enhancing trimeric Env immunogens in vaccines.

197 lnerable site can be designed and that these immunogens induce distinct Ab responses with epitope con

198 Our V1V2 immunogens induced distinct conformation-specific Ab res

199 ld with rationally designed epitope scaffold immunogens inducing Abs that recapitulate the epitope sp

200 ormation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody t

201 ing of a safe and effective HIV/AIDS vaccine immunogen is one of the main research priorities.

202 One approach to assess potential immunogens is to use mice expressing precursors of human

203 elicobacter pylori GroES (HpGroES), a potent immunogen, is a secreted virulence factor that stimulate

204 esulting in the conclusion that the envelope immunogen itself should be the primary consideration in

205 Including such peptides in vaccine immunogen may help to focus immune responses on common m

206 We conclude that different immunogens may be required to elicit bnAbs that have the

207 e high-mannose patch and show that different immunogens may be required to elicit these different cla

208 Germline-targeting immunogens must be capable of priming rare bnAb precurso

209 ully incorporated into a vaccine, TcdB-based immunogens must stimulate the production of neutralizing

210 ided boosting with a sequence of directional immunogens, native-like trimers with decreasing epitope

211 emagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 va

212 ign improvements that could eventually yield immunogens of practical value for solving the long-stand

213 icity of DS-SOSIP.4mut suggest utility as an immunogen or a serologic probe; moreover, the specific f

214 r HIV vaccine development, regardless of the immunogen or vaccine formulation.

215 hese animals could be altered only by strong immunogens or by immunization with HBV antigen-pulsed de

216 stabilized trimers may have utility as HIV-1 immunogens or in other antigen-specific contexts, such a

217 omology between the MVA- and DNA Gag-encoded immunogens (P = 0.04, r(2) = 0.47).

218 Our results demonstrate that immunogens presenting the different structural conformat

219 Mice vaccinated with our designed immunogens produced robust antibody responses to epitope

220 charide was conjugated to T-cell stimulating immunogen PS A1 from Bacteroides fragilis ATCC 25285/NCT

221 high-affinity conditions using a multivalent immunogen, rare VRC01-class B cells successfully compete

222 key aspects of HIV-1 Env immunogenicity and immunogen re-design, based on experimental data generate

223 Abs induced by the structurally constrained immunogens reacted preferentially with constrained V1V2

224 Abs induced by structurally unconstrained immunogens reacted preferentially with unconstrained V1V

225 ors), have been engineered to evaluate novel immunogens/regimens for effectiveness in driving bnAb re

226 Native-like HIV-1 Env immunogens representing distinct clades have been propos

227 thymus, the maternal or foster pup origin of immunogen-responding CD8(+) cells in foster pup spleens

228 ed in the first few weeks after weaning, all immunogen-responding CD8(+) T cells were pup derived by

229 At this age, 82% of immunogen-responding cells in the pup spleen were produc

230 Pup-derived immunogen-responsive CD8(+) cells persisted until at lea

231 tial antigen engagement and facilitate rapid immunogen screening, these antibodies are expressed as m

232 Advancement in immunogen selection and vaccine design that will rapidly

233 n developed for the generation of artificial immunogen sequences (so-called "centralized" sequences)

234 By homology to the HIV immunogen, seven CE were identified in SIV p27(Gag) Anal

235 dth considerably, suggesting that an optimal immunogen should elicit several antibodies from this fam

236 Ideally, Env immunogens should present broadly neutralizing antibody

237 that a proportion was positive for maternal immunogen-specific MHC class II tetramers.

238 Immunogens specifically designed to activate B cells bea

239 Current approaches to immunogen stabilization involve iterative application of

240 nverted the purified 3F7.A10 mAb into a weak immunogen, suggesting that the mAb had formed immunogeni

241 ltiple trimers as sequential or simultaneous immunogens, targeting the germline precursors of bNAbs,

242 We engineered an immunogen that binds to VRC01-class bnAb precursors and

243 , we address the challenge of identifying an immunogen that can elicit potent, broadly protective, an

244 ture-based development of an H1 HA stem-only immunogen that confers heterosubtypic protection in mice

245 es (2015) identify an exciting new candidate immunogen that could initiate the production of these ty

246 FLSC is a CD4-gp120 fusion immunogen that exposes cryptic gp120 epitopes to the imm

247 Advances in the design of immunogens that antigenically mimic the HIV envelope gly

248 ected toward generating soluble trimeric Env immunogens that assume native structures.

249 Designing immunogens that can induce conformation-specific antibod

250 ial to understand in order to design optimal immunogens that can induce different classes of bnAbs ag

251 strategies are needed to design recombinant immunogens that display these critical immune targets.

252 These results may aid the design of immunogens that elicit antibodies to the trimer apex.

253 However, to date, HIV-1 Env immunogens that elicit broadly neutralizing antibodies h

254 The design of immunogens that elicit broadly reactive neutralizing ant

255 technology was effectively used to design HA immunogens that elicited antibodies that neutralized H5N

256 ded successive H1 HA stabilized-stem (HA-SS) immunogens that lack the immunodominant head domain.

257 We identified immunogens that minimized non-neutralizing V3 responses

258 was shown to be sufficient to produce potent immunogens that possess the key characteristics of conve

259 e is structurally polymorphic, and designing immunogens that present different conformations is cruci

260 One possible hindrance has been the lack of immunogens that properly mimic the native conformation o

261 show important differences between the noted immunogens that should be borne in mind when considering

262 Here we compared two immunogens: the ligand-free BG505 SOSIP.664 trimer and t

263 mice were protected, yet at low doses of the immunogen, these antibodies neutralized virus poorly, an

264 ond successfully designing several novel HCV immunogens, this study demonstrates the principle that n

265 No immunogen to date has reliably elicited broadly neutrali

266 ncrease the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enha

267 cies cytokine RANKL was successfully used as immunogen to induce anti-RANKL immune response.

268 ll-ordered Env trimer that could serve as an immunogen to initiate a V2-apex bnAb response.

269 We then used the immunogen to isolate VRC01-class precursor naive B cells

270 vaccine development is the production of an immunogen to mimic native, functional HIV-1 envelope tri

271 onverting the allergen into a hypoallergenic immunogen to restrain health hazards during desensitizat

272 Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen can augm

273 for determining the ability of potential HIV immunogens to accurately replicate the glycosylation pat

274 are reviewed: firstly, the use of sequential immunogens to activate B cells to express bNAbs; secondl

275 se HIV strains, but strategies for designing immunogens to elicit bnAbs have not been identified.

276 odies may help to inform the design of HIV-1 immunogens to elicit broadly neutralizing antibodies.

277 h HIV and influenza virus, and the design of immunogens to elicit them is a goal of vaccine research

278 e I), we performed structure-based design of immunogens to induce antibody responses to this epitope.

279 ilized amyloid protofibrils could be used as immunogens to prepare conformation-specific antibodies a

280 entifies features that should be mimicked in immunogens to prevent EPCR binding.

281 line precursors and are therefore unsuitable immunogens to prime supersite-bnAb responses.

282 ings will be instrumental for devising novel immunogens to protect simultaneously against all four se

283 We evaluated whether adding the T cell immunogens UL19 (capsid protein VP5) and UL47 (tegument

284 Therefore, adding the T cell immunogens UL19 and UL47 to the gC2/gD2 vaccine did not

285 fficiently to soluble forms of the optimized immunogen, unless it is highly multimerized.

286 otein with enhanced enzymatic activity as an immunogen, we generated fully human monoclonal antibodie

287 By using novel engineered DBP immunogens, we validate that the prime targets of protec

288 hile Con-S Env was a single sequence, mosaic immunogens were a set of three Envs optimized to include

289 Novel immunogens were designed to focus the antibody response

290 y of the human monoclonal Abs from which the immunogens were designed.

291 nses induced by the structurally constrained immunogens were more broadly reactive and had higher tit

292 The Env immunogens were selected from envs emerging during the e

293 radoxically decreased binding to the foreign immunogen, whereas other mutations conferred increased f

294 nces and nine scaffold proteins to construct immunogens which were tested using various immunization

295 The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external

296 They respond to immunogen with Abs that, upon boosting, appear more rapi

297 clic defensin protein, as well as a bivalent immunogen with two copies of the epitope on the E2 surfa

298 to other populations vaccinated with similar immunogens with different modes and intensity of transmi

299 resulted in multiple homogeneous cross-clade immunogens with the potential to advance HIV vaccine dev

300 odies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward an effective